A Study of Optical Imaging With Light From Radiotracers in Cancer Patients

Memorial Sloan Kettering Cancer Center (MSK)

Status

Active, not recruiting

Conditions

Thyroid Cancer

Treatments

Diagnostic Test: Cerenkov luminescence imaging.

Study type

Observational

Funder types

Other

Identifiers

NCT03484884

17-538

Details and patient eligibility

About

The purpose of this study is to test Cerenkov luminescence imaging, which is a different way to take pictures of thyroid cancer and/or any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region.

Enrollment

102 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participant is 18 years of age or old
Participant must meet one of the following:
- Patients with thyroid cancer scheduled for thyroid ablation therapy with 131I
- Patients with any tumors with (existing or suspected) nodal metastases in the neck, supraclavicular, axillary and/or inguinal region who are scheduled to receive a clinical FDG PET/CT scan
- Patients with metastatic prostate cancer who are schedule for Xofigo therapy with 223Ra
- Patients scheduled to receive a standard of care 66Ga-DOTA-TATE or [18f]-PARPi PET scan in the Nuclear Medicine Clinic
- Patient undergoing Lu-DOTA TATE treatment in the Nuclear Medicine Clinic

Exclusion criteria

Patients imaged for Cerenkov luminescence are going to be required to be in a darkened enclosure for at least 10 minutes and sit still during image acquisition. Any conditions that would prevent this will exclude the patients. This includes patients who unable to sit in a dark environment, have claustrophobic, inability to sit still for a few minutes
Any other past medical, physiological or demographic concerns. This includes any patients with skin blemishes that are present at the dermis over the tumor, as these are of particular interest for use of this technique. This also includes open wounds on the area of interest.